Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214101 | 0.91 | RAB9A (0.48) | CYP2C9CYP2C19GAAMAPTSMN1; SMN2 | |
| SCHEMBL14829587 | 0.77 | BACE1 (0.53) | BACE1MAPK1POLBSCD5 | |
| SCHEMBL27364822 | 0.77 | BACE1 (0.53) | CYP2C9CYP2C19BACE1MAPK1SCD5 | |
| SCHEMBL21223183 | 0.74 | BACE1 (0.51) | GAASMN1; SMN2HPGDNPSR1ALDH1A1 | |
| SCHEMBL21223180 | 0.74 | BACE1 (0.51) | GAASMN1; SMN2HPGDNPSR1ALDH1A1 | |
| SCHEMBL12944620 | 0.74 | BACE1 (0.51) | SMN1; SMN2BACE1MAPK1POLBLMNA | |
| SCHEMBL3431817 | 0.74 | CYP2C19 (0.57) | CYP2C9CYP2C19GAAMAPTSMN1; SMN2 | |
| SCHEMBL24384975 | 0.73 | NAMPT (0.41) | SMN1; SMN2NAMPTSCD5 | |
| SCHEMBL7967450 | 0.73 | CYP2C9 (0.73) | CYP2C9CYP2C19GAAMAPTSMN1; SMN2 | |
| SCHEMBL14095299 | 0.72 | BACE1 (0.49) | SMN1; SMN2BACE1MAPK1LMNASCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108699077-B | Heterocyclic compounds as RSV inhibitors | 英安塔制药有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3402799-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017123884-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123884-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | CYP2C9 133/4885CYP2C19 26/4885GAA 602/4885 |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | CYP2C9 133/4885CYP2C19 26/4885GAA 602/4885 |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | CYP2C9 133/4885CYP2C19 26/4885GAA 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.